隐形牙套制造商Byte因患者报告的严重牙齿损伤和颌骨问题，于2024年停止向澳大利亚客户销售[1]。该公司的产品在获得澳大利亚医疗用品管理局（TGA）批准时仅用时3天且未经审计[1]，随后监管漏洞进一步被曝光。
不良事件报告数量的急剧增加凸显了问题的严重性。截至2024年11月，Byte累计仅收到2份不良事件报告，但随后一个月内该数字增至77份[1]。这些不良事件报告涉及牙齿断裂、颌骨锁定、骨质流失和牙龈衰退等多种伤害[1]。患者为接受治疗支付了3300至3700澳元[1]，却因器械失效或造成的伤害而无法获得牙医协助[1]。
监管缺陷的范围远超Byte一家公司。TGA对超过28000种低风险医疗器械基本无监督[1]，制造商虽然需要在30天内提交不良事件报告，但并无强制执行机制[1]。自2012年以来，第一类医疗器械共产生5424份不良事件报告，其中包括714起伤害事件和24例死亡[1]。
Clear aligner company Byte ceased selling to Australian customers in 2024 following a dramatic spike in reports of serious dental and jaw complications, according to an investigation into the company's regulatory oversight.[1] The withdrawal exposed significant gaps in how Australia's Therapeutic Goods Administration (TGA) monitors low-risk medical devices, with the regulator overseeing more than 28,000 such products with minimal active supervision.[1]
Byte's troubles began despite a remarkably swift approval process. The company received regulatory clearance in July 2022 after just three days of review, with no independent audit conducted.[1] By November 2024, the company had reported only two adverse events to authorities; within the following month, that figure surged to 77 reports.[1] The complaints documented broken teeth, locked jaws, bone loss, and gum deterioration among patients who had paid between $3,300 and $3,700 for treatment.[1] Many patients reported being unable to obtain dental assistance once the aligners caused injury or failed to function as intended.[1]
The case reflects broader regulatory vulnerabilities. Since 2012, Class I medical devices in Australia have generated 5,424 adverse event reports overall, including 714 instances of harm and 24 deaths.[1] While manufacturers are required to submit adverse event reports within 30 days, the TGA has no enforcement mechanism to ensure compliance, allowing companies to self-determine whether incidents warrant reporting.[1]